Work

Economic evaluation of new targeted therapies for the first‐line treatment of patients with metastatic renal cell carcinoma

Year: 2011

Type: article

Source: British Journal of Urology

DOI: 10.1111/j.1464-410x.2010.09957.x

Authors: Ágnes Benedict, Robert A. Figlin, Per Sandström, Ulrika Harmenberg, Anders Ullén, Claudie Charbonneau, Rickard Sandin, Edit Remák, Subramanian Hariharan, Sylvie Négrier

Institutions: United BioSource Corporation (United Kingdom), Cedars-Sinai Medical Center, Karolinska University Hospital, Pfizer (United States), Pfizer (Sweden), Centre Léon Bérard

Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Pfizer, GlaxoSmithKline

OpenAlex ID: W1570088421

FWCI: 12.13

Cites: 22

Cited by: 45

Related to: 10